Novel homobarringtonie‑containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy

  • Authors:
    • Jingsong He
    • Li Li
    • Jingjing Zhu
    • Weiyan Zheng
    • Wenjun Wu
    • Yanlong Zheng
    • Xiujin Ye
  • View Affiliations

  • Published online on: September 27, 2017     https://doi.org/10.3892/ol.2017.7084
  • Pages:7597-7607
Metrics: PDF 0 views | HTML 0 views
0

Abstract

The current study investigated the efficacy and safety of a novel treatment regime consisting of homobarringtonie, cytosine arabinoside and etoposide (HCE) for the treatment of primary acute myeloid leukemia (AML). In the present study, 141 patients diagnosed with AML were divided into the HCE (n=47) and the conventional AML therapy, consisting of idamycin combined with cytarabine (IA; n=94), treatment groups. The measured patient outcome parameters were the emission and response rates, as well as medication‑induced adverse events, with a median follow‑up time of 28 months. There was no significant difference in the 3‑year relapse‑free survival rate between the HCE and IA treatment groups. The occurrence and severity of hematological or non‑hematological toxicity did not differ between the two groups. However, of the 26 patients that demonstrated a poor response to the IA treatment, 19 cases were administered the HCE treatment and 14 of these patients achieved complete remission (CR). Of the 10 patients that demonstrated a poor response to the HCE treatment, 8 patients were administered the IA treatment and 7 of these achieved CR. Therefore, HCE may be an effective treatment regimen for patients with primary AML. As there was no cross‑resistance between the HCE and IA regimens, HCE may be an alternative option for patients that respond poorly to IA induction therapy.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
He, J., Li, L., Zhu, J., Zheng, W., Wu, W., Zheng, Y., & Ye, X. (2017). Novel homobarringtonie‑containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy. Oncology Letters, 14, 7597-7607. https://doi.org/10.3892/ol.2017.7084
MLA
He, J., Li, L., Zhu, J., Zheng, W., Wu, W., Zheng, Y., Ye, X."Novel homobarringtonie‑containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy". Oncology Letters 14.6 (2017): 7597-7607.
Chicago
He, J., Li, L., Zhu, J., Zheng, W., Wu, W., Zheng, Y., Ye, X."Novel homobarringtonie‑containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy". Oncology Letters 14, no. 6 (2017): 7597-7607. https://doi.org/10.3892/ol.2017.7084